Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.67 Average Target Price from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATECGet Free Report) have been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $17.67.

A number of analysts have weighed in on the company. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Piper Sandler increased their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th.

Check Out Our Latest Stock Analysis on Alphatec

Insider Buying and Selling at Alphatec

In other news, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total value of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at $62,324,895.92. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the transaction, the executive vice president now owns 668,977 shares in the company, valued at $7,245,020.91. The trade was a 4.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 337,321 shares of company stock worth $3,828,060. Insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Lido Advisors LLC boosted its stake in shares of Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after buying an additional 953 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Alphatec by 0.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock valued at $2,873,000 after purchasing an additional 1,120 shares during the last quarter. Comerica Bank lifted its stake in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Alphatec by 14.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock valued at $100,000 after purchasing an additional 1,342 shares during the last quarter. Finally, Atria Investments Inc lifted its stake in Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Up 0.2 %

Shares of NASDAQ:ATEC opened at $9.29 on Friday. The firm has a market cap of $1.34 billion, a P/E ratio of -7.26 and a beta of 1.39. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a 12-month low of $4.88 and a 12-month high of $14.88. The business has a fifty day simple moving average of $10.95 and a 200 day simple moving average of $8.76.

Alphatec (NASDAQ:ATECGet Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Alphatec Company Profile

(Get Free Report

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Featured Stories

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.